sr 48692 has been researched along with Disease Models, Animal in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Ehata, S; Miyauchi, K; Miyazawa, K; Miyazono, K; Morishita, Y; Takahashi, K | 1 |
| Cui, H; Liu, Y; Yi, L; Zhang, Y; Zhu, S | 1 |
| McCormick, SE; Stoessl, AJ | 1 |
4 other study(ies) available for sr 48692 and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Neurotensin receptor 1 signaling promotes pancreatic cancer progression.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice, Inbred BALB C; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Pyrazoles; Quinolines; Receptors, Neurotensin; Signal Transduction | 2021 |
Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Keratinocytes; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Neurotensin; Pyrazoles; Quinolines; Receptors, Neurotensin; Tumor Cells, Cultured | 2014 |
Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fluphenazine; Globus Pallidus; Male; Mastication; Prodrugs; Pyrazoles; Quinolines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Neurotensin; Stereotyped Behavior; Substantia Nigra | 2003 |